KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Enterprise Value: 2009-2025

Historic Enterprise Value for Acadia Pharmaceuticals (ACAD) over the last 17 years, with Sep 2025 value amounting to $2.8 billion.

  • Acadia Pharmaceuticals' Enterprise Value rose 38.65% to $2.8 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $553.7 million, marking a year-over-year decrease of 3.78%. This contributed to the annual value of $2.3 billion for FY2024, which is 51.14% down from last year.
  • Per Acadia Pharmaceuticals' latest filing, its Enterprise Value stood at $2.8 billion for Q3 2025, which was down 3.33% from $2.8 billion recorded in Q2 2025.
  • In the past 5 years, Acadia Pharmaceuticals' Enterprise Value registered a high of $4.7 billion during Q4 2023, and its lowest value of $1.8 billion during Q2 2022.
  • Moreover, its 3-year median value for Enterprise Value was $2.7 billion (2023), whereas its average is $2.8 billion.
  • Per our database at Business Quant, Acadia Pharmaceuticals' Enterprise Value crashed by 63.69% in 2021 and then skyrocketed by 91.47% in 2023.
  • Quarterly analysis of 5 years shows Acadia Pharmaceuticals' Enterprise Value stood at $3.2 billion in 2021, then decreased by 9.02% to $2.9 billion in 2022, then soared by 59.93% to $4.7 billion in 2023, then plummeted by 51.14% to $2.3 billion in 2024, then spiked by 38.65% to $2.8 billion in 2025.
  • Its Enterprise Value was $2.8 billion in Q3 2025, compared to $2.8 billion in Q2 2025 and $2.1 billion in Q1 2025.